Natco Pharma Update by Epic Research

Natco Pharma’s marketing partner in the USA, Breckenridge Pharmaceutical, Inc. (BPI), has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets. Both the entities’ Paragraph IV ANDA was filed on the First-to-File date and expected to be the only generic that is entitled to the 180-day exclusivity period.



Real Time News & Trading Trends Keep Liking #EpicResearch




Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+



For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH

Posted in: Indian Market Tips